Advertisements

Arilin rapid

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Arilin rapid

Property Description
Active ingredient Metronidazole (a single, monoseptic agent)
Form Soft vaginal capsules (ovules)
Pharmacological class Nitroimidazole derivative
General action Antimicrobial (Antibiotic and Antiprotozoal)
Origin Synthetic chemical compound

What Type of Medicine is Arilin rapid and What is its Composition?

Arilin rapid is a highly specialized pharmaceutical preparation whose sole active component is the synthetic compound Metronidazole. This agent is universally classified as a nitroimidazole derivative, placing it firmly within the antimicrobial pharmacological class, which provides both antibiotic and antiprotozoal activity. The core ingredient, Metronidazole, is a key medication for treating localized infections by stopping the growth of certain types of harmful bacteria. This classification confirms that the medicine is designed to neutralize specific microscopic organisms responsible for microbial imbalances.

Arilin rapid is known for its rapid formulation, a distinctive feature intended to maximize local therapeutic effect. Metronidazole itself is clinically recognized for its high efficacy against obligate anaerobes, including the Bacteroides fragilis group, often involved in complex local infections.

Arilin rapid: The Purpose and Form of a Vaginal Capsule

The preparation is formulated as a soft vaginal capsule—often clinically referenced as an ovule—and is designed exclusively for topical vaginal application. This targeted local approach is a differentiating factor from oral Metronidazole forms that treat systemic infections. The fundamental purpose of the preparation is to clear localized infections by initiating a rapid and concentrated bactericidal and antiprotozoal action against susceptible pathogens. The intravaginal administration of Metronidazole achieves effective local concentrations with a reduced risk of systemic exposure compared to oral therapy. This delivery method ensures the active compound achieves maximum therapeutic concentration directly at the source of the microbial imbalance.

Regulatory References

  1. Metronidazole: MedlinePlus Drug Information
  2. NIH MedlinePlus
Advertisements

What side effects are possible with Arilin rapid?

Possible Side Effects and Safety Information

This information describes the documented safety profile and adverse reactions for Arilin rapid (Metronidazole), as classified in regulatory labeling.


Adverse Reactions

Adverse reactions are classified by frequency and System Organ Class (SOC) in regulatory documents. Common side effects (occurring in 1% to 10% of patients) often include gastrointestinal disturbances, such as nausea, diarrhea, vomiting, and a metallic taste in the mouth.

Classification Examples of Documented Adverse Reactions
Nervous System Encephalopathy, Convulsions, Peripheral Sensory Neuropathy, Ataxia
Hematologic Leucopenia, Neutropenia, Agranulocytosis
Hepatobiliary Acute Hepatic Failure, Cholestatic Hepatitis
Dermatologic Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN)

Serious Adverse Reactions

Specific rare but clinically significant adverse events include encephalopathy, aseptic meningitis, and potentially fatal severe hepatotoxicity, particularly documented in patients with Cockayne syndrome, where the drug is contraindicated. Severe cutaneous adverse reactions (SCARs), such as SJS and TEN, are also officially documented.

Safety Restrictions and Monitoring

Strict limitations apply to the use of Arilin rapid. Alcohol consumption must be avoided during therapy and for at least 48 hours after treatment stops due to the risk of a disulfiram-like reaction. Caution and potential dose adjustment are required for patients with severe hepatic impairment. Treatment exceeding 10 days may necessitate clinical and laboratory monitoring, specifically leucocyte counts, due to the risk of blood dyscrasias. The label contains a warning that the drug has shown carcinogenic activity in animal studies, advising that unnecessary use should be avoided.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help for Arilin rapid (Metronidazole) is strictly defined by regulatory guidance, focusing on documented systemic exposure risks. The manifestations documented in official labeling primarily affect the gastrointestinal tract and the central nervous system. Documented clinical signs in an overdose situation include nausea and vomiting. More serious systemic manifestations involve neurological symptoms such as ataxia (loss of muscle coordination) and peripheral neuropathy, as well as severe outcomes including convulsive seizures. These severe neurological effects are documented in association with high systemic exposure.

Regulatory authorities issue clear guidance on when urgent medical assistance is required. Immediate action is mandated if an individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. In such severe scenarios, individuals must contact emergency services immediately, and the poison control helpline should be called.

The official overdose management strategy is constrained by the fact that no specific antidote is known for Metronidazole. Therefore, treatment, as defined in regulatory labeling, must consist exclusively of symptomatic and supportive therapy.

Advertisements

Therapeutic Uses of Arilin rapid

What Arilin rapid Treats: Main Uses and Benefits

Arilin rapid is commonly used across therapeutic domains where short-term symptomatic assistance is appropriate for infectious conditions. It is applied across domains where additional symptomatic support is needed for managing acute or heightened distress. This medication is commonly used to help with conditions involving episodic or fluctuating manifestations, such as conditions presenting with systemic or localized discomfort. This condition is relevant in clinical settings marked by heightened patient distress, and the medication may be part of symptomatic management which contributes to improved day-to-day comfort during symptomatic periods.

Relief from Distressing Symptom Clusters

The medication is used for managing symptom clusters that may become intense or disruptive, and generally supports the patient during difficult episodes by easing distress. This plays a role in managing symptoms related to physical discomfort like unpleasant vaginal odor and abnormal discharge (often thin, grey, or white). It is applied across therapeutic domains where additional symptomatic support is needed for managing these specific manifestations.

Support for Localized Comfort and Functional Stability

The therapeutic benefit is also relevant for managing symptoms that interfere with daily comfort, such as associated itching, burning, and irritation. This action generally supports the patient during difficult episodes by easing distress and may help maintain a sense of stability when symptoms are more noticeable.


Quick Fact: Is commonly used to help with conditions involving episodic or fluctuating manifestations that require short-term symptomatic assistance.

Regulatory References

  1. NIH MedlinePlus overview of Metronidazole Vaginal
Advertisements

Eligibility and Restrictions for Use

The eligibility for using Arilin rapid is strictly defined by regulatory guidelines, focusing on absolute contraindications, patient age, and specific pre-existing health conditions related to metronidazole.

Eligibility Structure: Who is Allowed and Who is Excluded

Category Eligibility Rule (Based on Official Labeling)
Populations Allowed Adult females and post-menarchal adolescents, typically 12 years of age and older.
Absolute Contraindications Patients with a known hypersensitivity to Metronidazole, other nitroimidazole derivatives, or any component of the formulation.
History of taking disulfiram within the last two weeks, or patients with Cockayne Syndrome.
Conditional Use/Caution Patients with severe hepatic disease, central nervous system (CNS) disease (e.g., history of seizures), or a history of blood disorders.

Age- and Life Stage-Related Eligibility

Age Group / State Regulatory Status of Use
Children under 12 Safety and effectiveness have not been established; use is generally restricted to post-menarchal females.
Geriatric Patients No specific limitations, but caution is advised due to the higher likelihood of age-related hepatic impairment.
Pregnancy Use is not recommended unless considered essential by a physician, and the potential benefit is deemed to outweigh the risk.
Lactation (Breastfeeding) Women are usually advised to discontinue nursing during treatment and for a specified period (e.g., 24 to 48 hours) after the last dose, as metronidazole passes into breast milk.

These official statements structure eligibility by establishing mandatory non-eligibility for specific conditions and individuals, while requiring careful medical consideration for use in other populations (e.g., those with severe liver or CNS disease) to limit systemic exposure.

Advertisements

What should I know about interactions with other medicines?

The interaction profile for Arilin rapid (Metronidazole) is primarily defined by systemic effects reported in official regulatory documents, despite the low absorption of the vaginal capsule.

Contraindicated Combinations and Substances

Classification Interacting Substance/Product
Formal Contraindication Disulfiram (within the last two weeks)
Pharmacodynamic Restriction Alcohol (Ethanol) or Propylene Glycol
Administration Restriction Other Intravaginal Preparations (e.g., progesterone gel)

Co-administration with Disulfiram is explicitly prohibited due to the risk of psychotic reactions. The consumption of Alcohol or Propylene Glycol is restricted during therapy and for at least 24 hours to 3 days after the final dose, as documented in official labeling, to avoid a disulfiram-like reaction.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Regulatory sources identify agents that formally modify Metronidazole exposure or potentiate other drug effects:

  • Oral Anticoagulants (e.g., Warfarin) experience a potentiated anticoagulant effect, which results in a documented prolongation of prothrombin time.
  • Lithium co-administration may result in elevated serum lithium concentrations.
  • Busulfan exposure may be significantly increased when co-administered.
  • Cimetidine (an enzyme inhibitor) may reduce Metronidazole clearance, while Phenobarbital (an enzyme inducer) may accelerate its elimination, altering systemic exposure.

These restrictions and interaction outcomes are explicitly stated in government labeling for Metronidazole.

Advertisements

Mechanism of Action

Selective Microbial Cytotoxicity

The mechanism of Arilin rapid is defined by the pharmacodynamics of its active ingredient, metronidazole, a prodrug that requires chemical activation to function. This activation is highly selective, occurring only when the molecule accepts electrons from low-redox potential enzymes, specifically nitroreductase, found exclusively within susceptible anaerobic bacteria and protozoa.

Once activated, the highly reactive intermediate, the nitroso radical, immediately initiates a destructive cascade. Its ultimate target is the microbial DNA, where it forms covalent bonds leading to strand breakage and disruption of the nucleic acid synthesis pathway. This genetic destruction results in rapid, concentration-dependent bactericidal and antiprotozoal action, eliminating the susceptible microbial population.

This mechanism is constrained by oxygen presence (futile cycling) and the lack of activating enzymes in aerobic organisms. This lack of interaction on aerobic systems defines its selectivity, confining the destructive effect to the target population.

Advertisements

Dosage and Administration Information

How to Use Arilin rapid

Arilin rapid is designed exclusively for topical vaginal application as a soft capsule, or ovule. Its use adheres to a very specific, high-dose, short-course protocol, defining the administration pattern. All dosing and procedural details are based on standard prescribing information.

Official Administration Protocol

Usage Element Standard Application (Adults)
Route of Administration Intravaginal (Topical)
Standard Dose 1000 mg Metronidazole (one capsule)
Frequency and Duration Typically administered as a single application. Some documented regimens include one capsule nightly for two consecutive days.
Timing & Positioning Must be administered at bedtime to ensure maximum retention and local effect. The patient should be lying on their back for deep insertion.
Preparation No preparation is required for the capsule form.
Pediatric Use Dosage and use in children and adolescents must be determined by a qualified healthcare professional.
Missed Dose For a two-day regimen, standard guidance typically directs inserting the capsule as soon as possible, without doubling the dose.

Connection to the Overall Use Protocol

The instructions establish a highly specific, short-term usage pattern defined by the topical route and a high 1000 mg dose of Metronidazole. This standardized framework dictates the precise quantity, administration technique, and treatment length required for the medicine's use, ensuring procedural consistency.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence for Arilin rapid

This section summarizes information from clinical research concerning the use of the active substance in Arilin rapid. This information is descriptive and is not a substitute for advice from a healthcare professional.


Overview of Therapeutic Role

The active component in Arilin rapid is a type of antibiotic investigated for its role in addressing bacterial infections. Clinical trials and research have explored its use in gynecological settings, particularly regarding its relationship with common bacterial conditions. These studies primarily evaluate the drug's effect when administered as a single-dose treatment compared to multi-day regimens or other treatments.

Efficacy Studies and Formulation

Research has explored the relationship between the single-dose formulation and the achievement of microbiological cure. Studies often define success based on the elimination of target bacteria following treatment and the resolution of symptoms. Findings generally report that the single-dose approach demonstrates outcomes comparable to those observed with longer-duration standard dosing, although patient populations and study designs can lead to varied results.


Comparative Trial Summary

Comparison Type Key Study Focus Reported Finding (Neutral)
Single-Dose vs. Multi-Day Microbiological and Clinical Status Single-dose was observed to have an equivalent outcome to the standard regimen.
Single-Dose vs. Alternative Treatment Treatment Compliance and Adverse Events The single-dose regimen was associated with higher patient compliance.

Further research continues to investigate the long-term effectiveness and potential recurrence rates following the use of the single-dose formulation across diverse patient groups.

Key Studies & References

  1. The Effectiveness of Single-Dose Metronidazole Therapy for Patients and Their Partners With Bacterial Vaginosis (Compared 7-day course vs. single-dose)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Arilin rapid (FAQ)

Q: How long does it usually take to feel better after using Arilin rapid?

Official research data primarily focuses on the time required to achieve a microbiological cure in studies, not the immediate onset of symptom relief. Studies indicate that the outcomes achieved with the single-dose treatment are comparable to those seen with longer regimens. Clinical improvement, meaning the start of symptom relief, has been generally noted in studies to occur within a few days after the completion of the treatment protocol.


Q: Why is Arilin rapid sometimes described as a 'single-dose' treatment?

The single-dose design is intended to deliver a high, localized concentration of the active ingredient directly to the site of infection. Regulatory documentation highlights the benefit of the short duration in promoting high patient compliance. Studies have shown that this approach achieves microbiological cure rates comparable to traditional, multi-day metronidazole courses.


Q: Can men use Arilin rapid?

Arilin rapid is specifically formulated as a vaginal capsule, or ovule, for topical application and is approved for conditions that occur in adult and post-menarchal females. The official prescribing information addresses eligibility requirements only for female patients. Its specialized route of administration indicates it is not suitable for male patients.


Q: Are there specific food or drinks to avoid while using Arilin rapid?

Regulatory documents highlight a critical restriction against consuming alcohol (ethanol) and products containing propylene glycol during therapy. While no specific restrictions on solid food types are generally listed, avoiding these substances is essential due to the risk of a severe disulfiram-like reaction. Regulatory labeling indicates this restriction should be followed for at least 24 hours to 3 days after the final dose.


Q: Are there any long-term effects associated with using Arilin rapid?

Official labeling documents for the active component, Metronidazole, advise that unnecessary or prolonged systemic use should be avoided. Given the single, short course of treatment, the standard usage protocol is generally considered to involve minimal systemic exposure, and official labeling focuses on acute and serious risks.


Q: Why do some people experience a change in taste after using Arilin rapid?

The metallic or unpleasant taste reported by some users is a documented adverse effect listed in official product documentation. This effect is thought to occur because a small amount of the active ingredient is absorbed into the bloodstream, even with topical vaginal application. It is classified as a common, temporary adverse reaction.


Q: Is Arilin rapid effective against yeast infections?

The active ingredient, Metronidazole, is classified as an antibiotic and antiprotozoal agent, specifically targeting susceptible anaerobic bacteria. Official sources do not list the medicine as a treatment for yeast (fungal) infections. The drug’s mechanism of action is not classified as effective against Candida or other fungal pathogens.


Q: What happens if Arilin rapid is used past its expiration date?

Official guidance advises against using the medicine past its stated expiration date. This rule is in place to maintain the product's guaranteed stability and ensure that the full concentration of the active ingredient is present. Using expired medicine may result in reduced efficacy and potentially compromise the expected therapeutic effect.


Q: Are there different strengths or doses of Arilin rapid?

The official administration protocol for Arilin rapid specifies a standardized single, high dose of 1000 mg of Metronidazole contained within one capsule. While Metronidazole exists in various strengths and forms, Arilin rapid is specifically defined by this particular formulation and dosage for its intended use.


Q: What are the reported success rates of Arilin rapid in clinical trials?

Regulatory summaries of clinical trials for the single-dose formulation typically report that its results, including rates of microbiological cure, are comparable to those achieved with standard, multi-day metronidazole regimens. Specific numerical success rates, such as percentage cure rates, can vary across different published studies and patient populations.


Q: Is Arilin rapid suitable for women who have gone through menopause?

Official eligibility guidelines confirm that there are generally no specific limitations for use in adult or geriatric patients, which includes post-menopausal women. The official documentation advises that caution may be necessary for geriatric patients due to the increased likelihood of age-related conditions, such as severe liver impairment.


Q: Does Arilin rapid affect birth control pills?

Regulatory documents for the active ingredient, Metronidazole, have reported that it may reduce the effectiveness of oral birth control pills. Official product information suggests that consultation with a healthcare professional regarding the potential need for an alternative or additional contraceptive method is warranted during the treatment period.


Q: Is it normal to have some discharge after using Arilin rapid?

Vaginal discharge, irritation, or itching are documented as potential adverse effects of metronidazole vaginal products in regulatory labeling. If a change in vaginal discharge or new vaginal symptoms is noted, regulatory guidance suggests these details be shared with a healthcare professional, as they can sometimes indicate a different or recurring infection.


Q: Can I use Arilin rapid if I am on my period?

Official guidance typically confirms that treatment with metronidazole vaginal products should generally not be interrupted if a menstrual period begins during the course of therapy. The regulatory guidance specifies that the medicine should be continued exactly according to the established treatment protocol.


Q: Does using Arilin rapid mean I shouldn't have sexual intercourse?

Patients using metronidazole vaginal products are generally advised not to have vaginal intercourse throughout the treatment period. Official product information includes this restriction, and patients are generally referred to the prescribing professional or the patient information leaflet for specific direction.


Q: Can I use Arilin rapid if I have other ongoing vaginal conditions?

Arilin rapid is approved only for specific types of bacterial infections. Regulatory documents often note that having other ongoing vaginal conditions, such as abnormal bleeding or certain sexually transmitted infections, can sometimes be a contraindication or require specialized medical evaluation before use.


Q: Does Arilin rapid contain hormones?

The compositional profile of Arilin rapid lists Metronidazole as its sole active ingredient, which is classified as a synthetic antibacterial and antiprotozoal agent. Official documentation confirms that the product does not contain hormones as part of its therapeutic formulation.


Q: Can Arilin rapid be used in conjunction with a probiotic?

Metronidazole is an antibiotic, and regulatory information notes that concurrent use with a probiotic may reduce the benefit of the probiotic. It is often recommended to stagger the administration, taking the probiotic at least one to two hours before or after the metronidazole product.


Q: Does Arilin rapid treat sexually transmitted infections (STIs)?

Arilin rapid is officially approved for specific bacterial infections, such as bacterial vaginosis, and also for certain protozoal infections like trichomoniasis, which is a sexually transmitted infection. However, the medicine is not indicated for the treatment of other broad sexually transmitted pathogens, such as Chlamydia or Gonorrhoeae.


Q: Can Arilin rapid interact with herbal supplements?

Official regulatory information generally states that there are no known interactions between metronidazole and most common herbal remedies or supplements. A potential interaction risk exists only if the herbal product is in a liquid form that contains alcohol or propylene glycol, as these substances must be avoided during therapy.


Q: Do official patient leaflets discuss using Arilin rapid with tampons?

Official patient leaflets typically advise patients not to use tampons, douches, or any other intravaginal products or devices during the treatment period. This restriction is in place because these products may interfere with the medicine’s absorption and local therapeutic effect.


Q: Can I use Arilin rapid if I have kidney issues?

Regulatory documents for the systemic form of Metronidazole state that while impaired kidney function does not majorly affect the drug itself, it can increase the concentration of its metabolites (breakdown products). For patients with kidney issues, regulatory information suggests consulting a healthcare professional for specific guidance regarding the use of the topical vaginal product.


Q: How soon after the treatment can I resume normal activities, according to official information?

Official documentation's only time-bound restriction relates to avoiding alcohol consumption for at least 24 hours to 3 days after the final dose. No specific official timeframes are typically published for resuming non-intravaginal activities like showering, swimming, or exercise.


Q: Is it normal to feel a mild irritation after using Arilin rapid?

Vaginal discomfort, burning, or mild local irritation is included among the adverse effects sometimes reported for metronidazole vaginal products. Official safety information advises that if this irritation is severe or does not quickly resolve, this event should be promptly reported to a healthcare professional for review.


Q: Can Arilin rapid cause dizziness?

Dizziness is an adverse reaction that has been officially documented for metronidazole. Regulatory documents classify this under Central Nervous System effects, which may include associated symptoms like vertigo or problems with coordination (ataxia).

Advertisements

How should Arilin rapid be stored and disposed of?

Official Storage and Disposal Requirements

Arilin rapid must be stored and disposed of according to regulatory requirements to maintain its stability and ensure safety.

Storage Conditions

The medicine must be kept out of the reach and sight of children. Store the product in its original container, ensuring it is tightly closed.

  • Temperature: Store the product below 30 C (86 F).
  • Protection: The ovules must be protected from direct light and excess moisture. Do not freeze the medicine.

Disposal Instructions

Do not use the medicine past its expiration date. Any unused or expired Arilin rapid must be disposed of properly. Consult a pharmacist or healthcare professional for specific advice on disposal. The product should not be thrown away in household waste or via wastewater systems, but according to local pharmaceutical waste handling regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Arilin rapid found in:

A-Z Index: